simFastBOIN

R-CMD-check CRAN status Lifecycle: stable License: MIT CRAN downloads Monthly downloads Codecov test coverage

Simulation tools for Bayesian optimal interval (BOIN) designs in phase I dose-finding trials. The documentation, with the six vignettes, is also available at https://gosukehommaex.github.io/simFastBOIN/.

Overview

simFastBOIN tabulates the BOIN decision boundaries, simulates the design to obtain operating characteristics, and applies the MTD selection rule used at the end of a trial. The simulation engine is written in C++.

The engine draws one uniform variate per patient, in enrollment order, and applies the decision rules in the same order as BOIN::get.oc(). With the same seed and matching arguments the two implementations agree trial by trial, not merely on average. The test suite checks this directly against the BOIN package rather than relying on a tolerance, so the claim is verifiable rather than asserted. A wider comparison ships with the package as inst/validation/compare-with-BOIN.R, which runs 200 configurations covering every combination of the options the two packages share, including extrasafe and titration.

Version 2.1.0 adds the time-to-event BOIN (TITE-BOIN) design, for toxicity that appears late in the assessment window or accrual that outpaces it. New patients are treated while earlier ones are still being followed, with the pending outcomes handled either by the single mean imputation of Yuan et al. (2018) or by the effective sample size of Lin and Yuan (2020). The decision table reproduces the published tables of Yuan et al. (2018) entry by entry, and whenever no patient is pending the simulated trials are identical to those of sim_boin() with the same seed.

The same version adds backfilling: patients who arrive while the dose escalation waits are treated at a lower dose that is safe and has shown a response. BF-BOIN (Zhao et al., 2024) backfills around the BOIN design, and BE-BOIN (Chen et al., 2026) around the time-to-event design. The operating characteristics of Table 4 of Zhao et al. (2024) are reproduced within simulation error.

For trials of two drugs given together, the same version adds the BOIN drug-combination design of Lin and Yin (2017), which looks for an MTD combination in a matrix of doses. It follows BOIN::get.oc.comb() trial by trial and reproduces the example of Yan et al. (2020) to the printed precision.

Version 2.2.0 adds the BOIN-ET design of Takeda et al. (2018), which decides from both the DLT and the response and selects the optimal biological dose (OBD), with its time-to-event (TITE-BOIN-ET) and backfill (BF-BOIN-ET) versions. The boundaries and the decision table of Takeda et al. (2018) are reproduced exactly, and the operating characteristics agree within simulation error with those of the ‘boinet’ and ‘bfboinet’ packages of the authors.

The same version adds the BOIN12 design of Lin et al. (2020), which treats each cohort at the dose with the most desirable balance of response and toxicity, measured by a utility. Its desirability score table reproduces Table 3 of the article in all 166 cells, and its engine agrees trial by trial with a separate Python implementation. The titration of the BOIN design can now stop at a given dose, which with an early stop at six patients gives the accelerated BOIN design of Kojima et al. (2024).

Its time-to-event version, TITE-BOIN12 (Zhou et al., 2022), treats new patients while the DLT or the response of earlier patients is still pending, which shortens the trial; when every decision waits for all the outcomes it gives exactly the trials of BOIN12.

Comb-BOIN12 (Lu et al., 2025) extends BOIN12 to two drugs given together and selects the optimal biological dose combination with a logistic model of the response. With one row of combinations its trials are those of BOIN12. TITE-Comb-BOIN12 applies its rules at the decision times of TITE-BOIN12. BOIN-ETC (Kakizume et al., 2024) divides the dose matrix of two drugs into subtrials along which the toxicity increases, runs BOIN-ET in each of them and selects the optimal dose combination by a utility, in the three versions of the article.

Whatever the design, oc_scenarios(), oc_results() and oc_compare() set the operating characteristics of several designs and scenarios side by side and judge them against the true MTDs and OBDs, with print() and plot() methods.

Installation

install.packages("simFastBOIN")

Or the development version:

# install.packages("pak")
pak::pak("gosukehommaEX/simFastBOIN")

Since version 2.0.0 the package contains compiled code, so a working C++ toolchain is needed to install from source (Rtools on Windows, Xcode command line tools on macOS).

Quick start

library(simFastBOIN)

oc <- sim_boin(
  target = 0.30,
  p_true = c(0.05, 0.15, 0.30, 0.45, 0.60),
  n_cohort = 10,
  cohort_size = 3,
  n_trials = 10000,
  seed = 123
)

oc

Compare several dose-toxicity scenarios under the same design:

sim_boin_multi(
  target = 0.30,
  scenarios = list(
    "MTD at dose 2"   = c(0.15, 0.30, 0.45, 0.60, 0.75),
    "MTD at dose 4"   = c(0.02, 0.06, 0.15, 0.30, 0.50),
    "All doses toxic" = c(0.40, 0.55, 0.65, 0.75, 0.85)
  ),
  n_cohort = 10,
  cohort_size = 3,
  n_trials = 10000,
  seed = 123
)

Look at the boundaries the design will actually use:

print(boin_boundary(target = 0.30, max_n = 18, extrasafe = TRUE), cohort_size = 3)

Read the dose decisions off a table, or off a figure for a protocol:

decisions <- boin_decision_table(target = 0.30, max_n = 18)

print(decisions, cohort_size = 3)
plot(decisions)                      # needs ggplot2

When toxicity can appear late, or patients arrive faster than they can be assessed, use the time-to-event design. Its decisions also depend on how long the pending patients have been followed:

tite <- tite_boin_decision_table(target = 0.30, max_n = 15)
print(tite, cohort_size = 3)

sim_tite_boin(
  target = 0.30,
  p_true = c(0.05, 0.15, 0.30, 0.45, 0.60),
  n_cohort = 10,
  cohort_size = 3,
  window = 3,          # a three month assessment window
  accrual_rate = 2,    # two patients a month
  n_trials = 10000,
  seed = 123
)

To backfill patients to lower doses while the escalation waits, give the response probabilities as well:

sim_bf_boin(
  target = 0.25,
  p_true = c(0.04, 0.12, 0.25, 0.43, 0.63),
  p_resp = c(0.10, 0.20, 0.30, 0.45, 0.58),
  n_cohort = 10,
  cohort_size = 3,
  window = 1,          # a one month assessment window
  accrual_rate = 3,    # three patients a month
  n_earlystop = 9,
  n_trials = 10000,
  seed = 123
)

For two drugs given together, give the true DLT rates as a matrix, with the levels of drug A in the rows and those of drug B in the columns:

sim_comb_boin(
  target = 0.25,
  p_true = matrix(c(0.02, 0.04, 0.08, 0.14,
                    0.08, 0.25, 0.42, 0.48,
                    0.25, 0.45, 0.50, 0.60), nrow = 3, byrow = TRUE),
  n_cohort = 16,
  cohort_size = 3,
  n_trials = 10000,
  seed = 123
)

Functions

Design

Function Purpose
boin_lambda() Escalation and de-escalation interval boundaries
boin_boundary() Integer decision boundaries by sample size
boin_decision_table() Decision table indexed by DLTs and patients
boin_stopping_table() Safety stopping boundary as a two-row table

Simulation

Function Purpose
sim_boin() Operating characteristics for one scenario
sim_boin_multi() Operating characteristics across scenarios
boin_simulate() Raw trial data from the engine
boin_isotonic() Isotonic estimates of the dose-toxicity curve
boin_select_mtd() MTD selection from completed trials

Time-to-event BOIN (TITE-BOIN)

Function Purpose
tite_boin_decision_table() Decision table with pending patients, for either method
sim_tite_boin() Operating characteristics, trial duration and suspensions of accrual
sim_tite_boin_multi() The same across scenarios
tite_boin_simulate() Raw trial data from the time-to-event engine

Backfilling (BF-BOIN and BE-BOIN)

Function Purpose
sim_bf_boin() Operating characteristics of BF-BOIN, with backfilled patients, responses and trial duration
sim_bf_boin_multi() The same across scenarios
bf_boin_simulate() Raw trial data from the BF-BOIN engine
sim_be_boin() Operating characteristics of BE-BOIN, backfilling with the time-to-event design
sim_be_boin_multi() The same across scenarios
be_boin_simulate() Raw trial data from the BE-BOIN engine

Drug combinations

Function Purpose
sim_comb_boin() Operating characteristics of the BOIN drug-combination design for one matrix of DLT rates
sim_comb_boin_multi() The same across scenarios
comb_boin_simulate() Raw trial data from the drug-combination engine
comb_boin_select_mtd() MTD combination selection from completed trials
comb_boin_next() Combination for the next cohort of a trial in progress, with print() and plot() methods

Optimal biological dose (BOIN-ET)

Function Purpose
boin_et_boundary() Boundaries of the BOIN-ET design for the DLT and the response
boin_et_decision_table() Decision table indexed by DLTs and responses
sim_boin_et() Operating characteristics with the selection of the optimal biological dose (OBD)
sim_boin_et_multi() The same across scenarios
boin_et_simulate() Raw trial data from the BOIN-ET engine
boin_et_select_obd() OBD selection from completed trials
sim_tite_boin_et() Operating characteristics of the time-to-event TITE-BOIN-ET design
sim_tite_boin_et_multi() The same across scenarios
tite_boin_et_simulate() Raw trial data from the TITE-BOIN-ET engine
sim_bf_boin_et() Operating characteristics of the backfill BF-BOIN-ET design
sim_bf_boin_et_multi() The same across scenarios

Optimal biological dose (BOIN12 and TITE-BOIN12)

Function Purpose
boin12_decision_table() Desirability score table indexed by patients, DLTs and responses
sim_boin12() Operating characteristics with the selection of the OBD
sim_boin12_multi() The same across scenarios
boin12_simulate() Raw trial data from the BOIN12 engine
boin12_select_obd() OBD selection from completed trials
sim_tite_boin12() Operating characteristics of the time-to-event TITE-BOIN12 design
sim_tite_boin12_multi() The same across scenarios
tite_boin12_simulate() Raw trial data from the TITE-BOIN12 engine

Optimal biological dose combinations (Comb-BOIN12 and TITE-Comb-BOIN12)

Function Purpose
sim_comb_boin12() Operating characteristics with the selection of the OBD combination
sim_comb_boin12_multi() The same across scenarios
comb_boin12_simulate() Raw trial data from the Comb-BOIN12 engine
comb_boin12_select_obd() OBD combination selection from completed trials
sim_tite_comb_boin12() Operating characteristics of the time-to-event TITE-Comb-BOIN12 design
sim_tite_comb_boin12_multi() The same across scenarios
tite_comb_boin12_simulate() Raw trial data from the TITE-Comb-BOIN12 engine

Optimal dose combinations (BOIN-ETC)

Function Purpose
sim_boin_etc() Operating characteristics of BOIN-ETC1, 2 or 3 with the selection of the optimal dose combination
sim_boin_etc_multi() The same across scenarios
boin_etc_simulate() Raw trial data from the BOIN-ETC engine
boin_etc_select_obd() Optimal dose combination selection from completed trials

3+3 design

Function Purpose
oc_3p3() Operating characteristics in closed form
sim_3p3() The same by simulation, as a check on the closed form
decision_table_3p3() Decision table of the design

Tables and figures

Function Purpose
oc_scenarios() True scenarios with the utilities and the true MTDs and OBDs
oc_results() Results of several designs and scenarios in one long table
oc_compare() Several designs judged against the true doses: correct selection, overdosing, sample size

Design options

Argument Effect
titration Treat one patient per dose until the first DLT, then switch to full cohorts
titration_doses Stop the titration at this dose; with n_earlystop = 6, the accelerated BOIN design of Kojima et al. (2024)
extrasafe Add a stopping rule at the lowest dose that triggers before elimination
bound_mtd Refuse to select a dose whose estimate exceeds the de-escalation boundary
n_earlystop Stop once the current dose has accrued this many patients and the design would stay
start_dose Dose level for the first cohort, ignored under titration
stay_on_1_of_3 Make one DLT out of three a stay rather than a de-escalation
min_mtd_sample Smallest number of patients for a dose to be eligible as the MTD

Note that n_earlystop defaults to 18 here, whereas BOIN::get.oc() defaults to 100, which in practice switches the rule off. Set it explicitly when comparing the two.

Late-onset toxicity: the TITE-BOIN design

method Pending outcomes handled by Boundaries refer to Default suspension rule
"imputation" Single mean imputation (Yuan et al., 2018) STFT Suspend accrual when more than half of the patients at the dose are pending
"ess" Effective sample size (Lin and Yuan, 2020) ESS Escalate only once two patients at the dose have completed the assessment

STFT is the total follow-up time of the pending patients divided by the length of the assessment window, and ESS adds to it the number of patients who have completed the assessment. Neither table depends on the length of the window. Both suspension rules can be set for either method with max_pending_ratio and min_completed.

A simulation needs the length of the window and the accrual rate in the same unit of time. Arrivals can be exponential (the default), uniform or fixed, and the time to DLT Weibull, with a share late_fraction of the DLTs in the second half of the window, or uniform. The follow-up of the pending patients can be weighted by a piecewise uniform prior for the time to DLT through prior_weights; both articles evaluate their designs with equal weights, the default.

How the implementation is checked:

Neither article reports operating characteristics that can be reproduced number for number: Yuan et al. (2018) give them as figures relative to the 3+3 design and as averages over randomly generated scenarios, and the tables of Lin and Yuan (2020) are for the keyboard and mTPI designs.

Backfilling: BF-BOIN and BE-BOIN

In BF-BOIN the dose escalation proceeds in fully staggered cohorts with the BOIN decision table. A patient who arrives while it waits is backfilled to the highest lower dose that has not been eliminated, has fewer than n_cap patients and has a response observed at or below it. Backfilled doses whose DLT rate becomes too high are closed, and when their data conflict with those of the current dose the escalation decides from the pooled data. BE-BOIN applies the same rules around the time-to-event design, with the suspension rules of Chen et al. (2025), and imputes the pending patients in every estimate. The MTD is selected from all patients, backfilled ones included.

Where the articles leave a detail of the simulation open, the package offers an argument: no_slot (a patient with nowhere to go waits or is turned away), conflict_dose (which conflicting dose anchors the pooled estimate) and resp_window, resp_late_fraction and resp_cor (the timing of responses and their correlation with DLTs).

How the implementation is checked:

See vignette("simFastBOIN-backfill") for the rules, the choices made where the articles are silent, and the comparison with Table 4.

Drug combinations

sim_comb_boin() implements the design of Lin and Yin (2017) as the BOIN package does in BOIN::get.oc.comb() with mtd.contour = FALSE, including the details that the package adds to the article: a candidate’s posterior probability is increased by 0.0005 per patient treated there, the trial can stop at n_earlystop, and the MTD is selected from (y + 0.05) / (n + 0.1) smoothed by Iso::biviso(). Note that n_earlystop defaults to 18 here, whereas BOIN::get.oc.comb() defaults to 100.

How the implementation is checked:

To run a trial, comb_boin_next() gives the combination for the next cohort from the numbers of patients and DLTs observed so far. It takes its decision with the same C++ code as the simulations, so the trial follows the rules whose operating characteristics sim_comb_boin() reports. BOIN::next.comb() differs from the simulations of BOIN::get.oc.comb() in a few rules, which the help page of comb_boin_next() lists.

nxt <- comb_boin_next(
  target = 0.25,
  n_pts = matrix(c(6, 6, 0, 0,
                   3, 3, 0, 0,
                   0, 0, 0, 0), nrow = 3, byrow = TRUE),
  n_tox = matrix(c(0, 1, 0, 0,
                   1, 2, 0, 0,
                   0, 0, 0, 0), nrow = 3, byrow = TRUE),
  current = c(2, 2)
)
nxt        # de-escalate to A1B2
plot(nxt)  # the dose matrix with the data and the decision

The waterfall design of Zhang and Yuan (2016), which looks for the MTD contour, is not provided. See vignette("simFastBOIN-combination").

Optimal biological dose: the BOIN-ET design

For targeted and immune therapies the aim is often the optimal biological dose (OBD), which weighs the response against the toxicity, rather than the MTD. The BOIN-ET design of Takeda, Taguri and Morita (2018) decides the next dose from both the DLT rate and the response rate at the current dose, with boundaries lambda1, lambda2 and eta1 that minimize the probability of an incorrect decision, and selects the OBD at the end of the trial.

boin_et_decision_table(target = 0.30, target_resp = 0.60, n = c(3, 6))

oc <- sim_boin_et(
  target = 0.30, target_resp = 0.60,
  p_true = c(0.05, 0.15, 0.25, 0.30, 0.35, 0.40),
  p_resp = c(0.05, 0.35, 0.55, 0.65, 0.75, 0.70),
  n_cohort = 12, cohort_size = 3, n_trials = 10000
)
oc

The rules follow the ‘boinet’ package (Yamaguchi, Takeda and Maruo, 2025), the reference implementation of the authors: the boundary search of boinet::gridoptim(), the admissibility of a dose re-derived after every cohort, and the estimators and selection rules of boinet::obd.select() (observed rates, model-averaged unimodal isotonic regression or fractional polynomial logistic regression; the highest response up to the estimated MTD or one of three utilities). The trial runs in C++ and the OBD selection too; the model-based estimates are computed once for every distinct set of final data. boin_et_select_obd() selects the OBD from completed trials.

Two rules differ from ‘boinet’, to keep to Takeda et al. (2018), who do not allow dose skipping during escalation: a dose excluded by its DLT data also excludes every higher dose, as in the later BF-BOIN-ET design of the same group, and an escalation from the highest dose ends the trial when that dose is excluded. boinet_compatible = TRUE applies the rules of ‘boinet’ exactly.

The time-to-event version, TITE-BOIN-ET (Takeda, Morita and Taguri, 2020), lets patients arrive while others are still assessed, and the backfill version, BF-BOIN-ET (Takeda, Zhu and Hirakawa, 2025), treats the patients who arrive in the meantime at lower doses with a promising response rate:

oc <- sim_tite_boin_et(
  target = 0.30, target_resp = 0.60,
  p_true = c(0.05, 0.15, 0.25, 0.30, 0.35, 0.40),
  p_resp = c(0.05, 0.35, 0.55, 0.65, 0.75, 0.70),
  n_cohort = 12, cohort_size = 3, window = 30, resp_window = 45,
  accrual_rate = 1 / 10, n_trials = 10000
)

oc_bf <- sim_bf_boin_et(
  target = 0.30, target_resp = 0.25,
  p_true = c(0.03, 0.05, 0.20, 0.22, 0.45),
  p_resp = c(0.05, 0.10, 0.50, 0.68, 0.70),
  n_cohort = 10, cohort_size = 3, window = 1, accrual_rate = 3,
  n_trials = 10000
)

The rules follow boinet::tite.boinet() and bfboinet::get.oc.backboinet().

How the implementation is checked:

For two drugs given together, sim_boin_etc() runs BOIN-ET in subtrials of the dose matrix, the BOIN-ETC design of Kakizume et al. (2024). inst/reproduce/reproduce_Kakizume2024.R compares it with the tables of the article and inst/validation/compare-with-BOINETC.R with the code of the authors.

See vignette("simFastBOIN-boin-et") for the decision rules, the selection of the OBD, the dose moves that differ from ‘boinet’, BOIN-ETC and the results of these checks.

Optimal biological dose: the BOIN12 design

The BOIN12 design of Lin et al. (2020) scores each patient by a utility, 100 for a response without DLT, 0 for a DLT without response and two values in between elicited from the clinicians (40 and 60 by default). The next cohort goes to the dose, among the current one and its neighbors, whose utility is most likely to exceed a benchmark, after the BOIN boundaries have ruled out an escalation from a toxic dose. The desirabilities can be tabulated for the protocol:

boin12_decision_table(target = 0.35, target_resp = 0.25)

Here target is the highest acceptable DLT rate and target_resp the lowest acceptable response rate. The operating characteristics follow the same pattern as the other designs:

oc <- sim_boin12(
  target = 0.35, target_resp = 0.25,
  p_true = c(0.05, 0.12, 0.27, 0.35, 0.50),
  p_resp = c(0.20, 0.35, 0.36, 0.37, 0.38),
  n_cohort = 12, cohort_size = 3, n_trials = 10000
)
oc

The table reproduces Table 3 of Lin et al. (2020) in all 166 cells (inst/reproduce/reproduce_Lin2020.R), and inst/validation/compare-with-escalation.R compares the operating characteristics with the BOIN12 design of the ‘escalation’ package.

The time-to-event version, TITE-BOIN12 (Zhou et al., 2022), treats new patients while the DLT or the response of earlier patients is still pending, replacing each pending outcome by its expectation given the time followed. The windows and the accrual rate are given in the same unit of time:

oc <- sim_tite_boin12(
  target = 0.35, target_resp = 0.25,
  p_true = c(0.05, 0.12, 0.27, 0.35, 0.50),
  p_resp = c(0.20, 0.35, 0.36, 0.37, 0.38),
  n_cohort = 12, cohort_size = 3,
  window = 1.5, resp_window = 2, accrual_rate = 3,  # months
  n_trials = 10000
)
oc

inst/reproduce/reproduce_Zhou2022.R compares the desirabilities of Table S.3 of the Supplement of Zhou et al. (2022) and the operating characteristics of BOIN12 and TITE-BOIN12 in their Figure 3.

See vignette("simFastBOIN-boin12") for the rules, the arguments that give the rules of the simulations of the articles, Comb-BOIN12 and TITE-Comb-BOIN12 for two drugs given together, a comparison of BOIN, BOIN-ET and BOIN12 on the same scenarios, and the results of these checks.

Why the trials stop

boin_simulate() records a reason for every trial, and sim_boin() reports the distribution in stop_reason_percent.

Reason Meaning
lowest_dose_eliminated The lowest dose was eliminated for toxicity
lowest_dose_too_toxic The extrasafe rule stopped the trial at the lowest dose
n_earlystop Enough patients had accrued at the current dose
max_sample_size The maximum number of patients was reached
max_cohorts All planned cohorts were completed

Checking the agreement with the BOIN package yourself

reference <- BOIN::get.oc(
  target = 0.30, p.true = c(0.05, 0.15, 0.25, 0.45, 0.60),
  ncohort = 20, cohortsize = 3, n.earlystop = 18, ntrial = 10000, seed = 6
)

ours <- sim_boin(
  target = 0.30, p_true = c(0.05, 0.15, 0.25, 0.45, 0.60),
  n_cohort = 20, cohort_size = 3, n_earlystop = 18, n_trials = 10000, seed = 6
)

all.equal(unname(ours$sel_percent), reference$selpercent)
all.equal(unname(ours$n_pts_dose), reference$npatients)
all.equal(unname(ours$n_tox_dose), reference$ntox)
all.equal(ours$percent_no_mtd, reference$percentstop)

Speed

Five doses, 20 cohorts of three, n_earlystop = 18 and 10,000 simulated trials, measured on one Windows machine:

Elapsed
BOIN::get.oc() 9.98 s
sim_boin() 0.07 s

That is about two orders of magnitude for this design. The ratio depends on the design and on the machine, so the code below re-measures it rather than asking you to take the table on trust.

scenario <- c(0.05, 0.15, 0.25, 0.45, 0.60)

system.time(
  BOIN::get.oc(target = 0.30, p.true = scenario, ncohort = 20, cohortsize = 3,
               n.earlystop = 18, ntrial = 10000, seed = 6)
)

system.time(
  sim_boin(target = 0.30, p_true = scenario, n_cohort = 20, cohort_size = 3,
           n_earlystop = 18, n_trials = 10000, seed = 6)
)

The time-to-event engine was timed on a similar design, five doses and 20 cohorts of three with the true DLT rates c(0.05, 0.15, 0.30, 0.45, 0.60), a three month window and two patients a month, 10,000 trials, all three runs together on one Windows machine:

Elapsed
sim_boin() 0.05 s
sim_tite_boin(), method = "imputation" 0.09 s
sim_tite_boin(), method = "ess" 0.11 s

Following patients over time costs about twice as much as the BOIN engine. The BOIN package has no time-to-event design, so there is no reference implementation of TITE-BOIN to time it against.

Comparing with the 3+3 design

The traditional 3+3 design is included as a comparator. Its operating characteristics are obtained in closed form rather than by simulation, so they carry no Monte Carlo error.

oc_3p3(p_true = c(0.30, 0.48, 0.67))

# The other definition of the MTD in common use
oc_3p3(p_true = c(0.30, 0.48, 0.67), mtd_rule = "expand")

sim_3p3() simulates the same design and exists to confirm the closed form. The result of either has the same component names as the result of sim_boin(), so the two designs can be tabulated side by side.

decision_table_3p3() shows the rule itself, with print() and plot() methods like those of the BOIN decision table. oc_compare() judges the 3+3 and BOIN designs against the true MTDs of oc_scenarios(), as shown in the section “Tables and figures” of vignette("simFastBOIN-introduction").

decision_table_3p3(mtd_rule = "expand")

Upgrading from version 1.3.2

Version 2.0.0 renames most functions, changes the argument order of sim_boin() and corrects several defects that affected numerical results. Simulations run with the same seed will not reproduce the version 1.3.2 output. See NEWS.md for the full list and the mapping of old names to new ones.

References

Liu, S. and Yuan, Y. (2015). Bayesian Optimal Interval Designs for Phase I Clinical Trials. Journal of the Royal Statistical Society: Series C, 64, 507-523.

Yan, F., Zhang, L., Zhou, Y., Pan, H., Liu, S. and Yuan, Y. (2020). BOIN: An R Package for Designing Single-Agent and Drug-Combination Dose-Finding Trials Using Bayesian Optimal Interval Designs. Journal of Statistical Software, 94(13), 1-32.

Yuan, Y., Lin, R., Li, D., Nie, L. and Warren, K. E. (2018). Time-to-Event Bayesian Optimal Interval Design to Accelerate Phase I Trials. Clinical Cancer Research, 24(20), 4921-4930.

Lin, R. and Yuan, Y. (2020). Time-to-Event Model-Assisted Designs for Dose-Finding Trials with Delayed Toxicity. Biostatistics, 21(4), 807-824.

Zhao, Y., Yuan, Y., Korn, E. L. and Freidlin, B. (2024). Backfilling Patients in Phase I Dose-Escalation Trials Using Bayesian Optimal Interval Design (BOIN). Clinical Cancer Research, 30(4), 673-679.

Chen, K., Chen, T.-Y., Zhang, Y., Lin, R. and Yuan, Y. (2025). Practical Considerations for Using the TITE-BOIN Design to Handle Late-Onset Toxicity or Fast Accrual in Phase I Trials. Clinical Cancer Research, 31(13), 2573-2580.

Chen, K., Zhao, Y., Takeda, K. and Yuan, Y. (2026). BE-BOIN: A Dose Optimization Design Accommodating Backfill and Late-Onset Toxicity. Therapeutic Innovation and Regulatory Science.

Lin, R. and Yin, G. (2017). Bayesian Optimal Interval Design for Dose Finding in Drug-Combination Trials. Statistical Methods in Medical Research, 26(5), 2155-2167.

Zhang, L. and Yuan, Y. (2016). A Practical Bayesian Design to Identify the Maximum Tolerated Dose Contour for Drug Combination Trials. Statistics in Medicine, 35(27), 4924-4936.

Takeda, K., Taguri, M. and Morita, S. (2018). BOIN-ET: Bayesian Optimal Interval Design for Dose Finding Based on Both Efficacy and Toxicity Outcomes. Pharmaceutical Statistics, 17(4), 383-395.

Takeda, K., Morita, S. and Taguri, M. (2020). TITE-BOIN-ET: Time-to-event Bayesian optimal interval design to accelerate dose-finding based on both efficacy and toxicity outcomes. Pharmaceutical Statistics, 19, 335-349.

Takeda, K., Zhu, J. and Hirakawa, A. (2025). BF-BOIN-ET: A Backfill Bayesian Optimal Interval Design Using Efficacy and Toxicity Outcomes for Dose Optimization. Pharmaceutical Statistics, 24, e2470.

Yamaguchi, Y., Takeda, K. and Maruo, K. (2025). boinet: An R Package for Bayesian Optimal Interval Design for Dose Finding Based on Both Efficacy and Toxicity Outcomes. The R Journal, 17(2), 15-34.

Lin, R., Zhou, Y., Yan, F., Li, D. and Yuan, Y. (2020). BOIN12: Bayesian Optimal Interval Phase I/II Trial Design for Utility-Based Dose Finding in Immunotherapy and Targeted Therapies. JCO Precision Oncology, 4, 1393-1402.

Zhou, Y., Lin, R., Lee, J. J., Li, D., Wang, L., Li, R. and Yuan, Y. (2022). TITE-BOIN12: A Bayesian Phase I/II Trial Design to Find the Optimal Biological Dose with Late-Onset Toxicity and Efficacy. Statistics in Medicine, 41(11), 1918-1931.

Lu, M., Zhang, J., Yuan, Y. and Lin, R. (2025). Comb-BOIN12: A Utility-Based Bayesian Optimal Interval Design for Dose Optimization in Cancer Drug-Combination Trials. Statistics in Biopharmaceutical Research, 17(2), 266-276.

Kakizume, T., Takeda, K., Taguri, M. and Morita, S. (2024). BOIN-ETC: A Bayesian Optimal Interval Design Considering Efficacy and Toxicity to Identify the Optimal Dose Combinations. Statistical Methods in Medical Research, 33(4), 716-727.

License

MIT (c) Gosuke Homma

mirror server hosted at Truenetwork, Russian Federation.